0.57 USD
▼-0.05-7.95%
盘后 0.60 +6.19%
2026-11-20
市值
$21.36M
市盈率
—
EPS
-2.50
股息率
—
52 周区间
0.56 – 1.87
成交量
274.38K
Beta
0.83
目标价
7.00
52W 低 0.5652W 高 1.87
价格走势
公司简介
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other...